Citation:Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al 2000

Citation

Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000 May;18(10):2095-103 Available from: http://www.ncbi.nlm.nih.gov/pubmed/10811675.

Critical appraisals

• Assign a critical appraisal

Critical appraisal link	Clinical question	Assigned to	Status
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al 2000	What is the optimal systemic therapy for stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al 2000 2	What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed
Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al 2000 3	What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?	Assoc. Prof. Nick Pavlakis	completed

Compare quality appraisals for each clinical question

• [[Clinical question:What is the optimal systemic therapy for stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|]] (compare critical appraisals)
• [[Clinical question:What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?|]] (compare critical appraisals)

Cited by

1. What is the optimal second-line therapy in patients with stage IV inoperable NSCLC?
2. What is the optimal systemic therapy for stage IV inoperable NSCLC?